Skip to main content

Table 1 Baseline characteristics

From: Does moxonidine reduce Achilles tendon or musculoskeletal pain in women with polycystic ovarian syndrome? A secondary analysis of a randomised controlled trial

 

Placebo (n = 18)

Moxonidine (n = 14)

p-value (t-test)

Age

29.9 ± 5.9

30.8 ± 6.9

0.70

BMI

29.6 ± 5.1

30.9 ± 6.0

0.49

WHR

0.96 ± 0.05

0.96 ± 0.04

0.69

SBP

108 ± 11

115 ± 16

0.17

DBP

69 ± 9

72 ± 10

0.45

MAP

82 ± 9

86 ± 10

0.28

Fasting BGL

4.7 ± 0.5

4.7 ± 0.4

0.84

HOMA index

4.4 ± 2.4

4.0 ± 1.7

0.64

Matsuda index

4.0 ± 2.8

3.3 ± 2.5

0.48

  1. BMI Body mass index, WHR Waist-to-hip circumference ratio, SBP Systolic blood pressure, DBP Diastolic blood pressure, MAP Mean arterial pressure, BGL blood glucose level, HOMA Homeostatic model assessment
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us